Frontlight ResearchEarly access
CompletedNo phase
Satisfaction of Patients With Erectile Dysfunction With the Use of Sildenafil Oral Suspension Compared to Orodispersible Tablets
Key facts
- Who runs it
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 55 people enrolled
- Started
- 1 Jun 2026
- Ended
- 31 Aug 2026
- Type of study
- Observational
- Treatments tested
- Sildenafil Oral Suspension Compared to Orodispersible Tablets
- Record updated
- 6 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18-75
- Male
- Sexually active (at least 2 sexual encounters per week)
- IIEF-EF between 11 and 25 at baseline
Who cannot take part
- previous pelvic surgery
- concomitant use of other ED therapies
- conical therapy with nitrates or other contraindicated drugs in combination with sildenafil
- patients who have lost vision in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION), whether or not this event was related to previous use of a phosphodiesterase type 5 (PDE5) inhibitor
- patients treated with guanylate cyclase stimulants, such as riociguat
- hypersensitivity to the active ingredient
- patients for whom sexual activity is not recommended (e.g. patients with serious cardiovascular disorders, such as unstable angina or severe heart failure)
- patients with severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal diseases, such as retinitis pigmentosa
- hypogonadism (total testosterone < 3.5 ng/mL)
- ED on a neurogenic basis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational retrospective study is to to evaluate treatment satisfaction with sildenafil oral suspension in patients with mild-to-moderate ED who were previously taking orodispersible sildenafil.
Read full original descriptionShow less
The secondary objective is to evaluate the efficacy and side effects of therapy with sildenafil oral suspension compared to orodispersible sildenafil.
Patients who took sildenafil orodispersible 50 mg for 3 months and subsequently took sildenafil oral suspension for another 3 months will be enrolled.
The group in the trial
- group 1
Treatment: Sildenafil Oral Suspension Compared to Orodispersible Tablets
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 October 2026